Inventor · disambiguated record
Levi A. Garraway
Also filed as: GARRAWAY LEVI · GARRAWAY LEVI A · GARRAWAY LEVI ALEXANDER
15 granted patents·18 pending applications·74 citations·filing 2007–2024
89Inventor score
Files withDANA FARBER CANCER INST INC14BROAD INST INC6GARRAWAY LEVI A6BRIGHAM & WOMENS HOSPITAL1CAPONIGRO GIORDANO1
Top patents by PatentIndex Score
33 records- 0195US7981609B2Methods for identifying and using SNP panelsBRIGHAM & WOMENS HOSPITAL·Filed 2007·Granted Jul 19, 2011·61 cites·12 claims
- 0287US2025034652A1C-RAF Mutants that Confer Resistance to RAF InhibitorsDANA FARBER CANCER INST INC·Filed 2024·Application pending·0 cites
- 0384US12146196B2C-RAF mutants that confer resistance to RAF inhibitorsDANA FARBER CANCER INST INC·Filed 2023·Granted Nov 19, 2024·0 cites·8 claims
- 0482US2024094208A1MEK1 Mutation Conferring Resistance to RAF and MEK InhibitorsDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 0576US9370551B2Compositions and methods of treating head and neck cancerCONG LE·Filed 2012·Granted Jun 21, 2016·9 cites·21 claims
- 0675US11788151B2C-RAF mutants that confer resistance to RAF inhibitorsDANA FARBER CANCER INST INC·Filed 2021·Granted Oct 17, 2023·0 cites·8 claims
- 0774US9629839B2C-RAF mutants that confer resistance to RAF inhibitorsDANA FARBER CANCER INST INC·Filed 2013·Granted Apr 25, 2017·2 cites·5 claims
- 0870US11789022B2MEK1 mutation conferring resistance to RAF and MEK inhibitorsDANA FARBER CANCER INST INC·Filed 2020·Granted Oct 17, 2023·0 cites·7 claims
- 0969US9279144B2Screening method for BRAF inhibitorsDANA FARBER CANCER INST INC·Filed 2013·Granted Mar 8, 2016·1 cites·7 claims
- 1064US10788496B2MEK1 mutation conferring resistance to RAF and MEK inhibitorsDANA FARBER CANCER INST INC·Filed 2017·Granted Sep 29, 2020·0 cites·5 claims
- 1162US10968484B2Methods of identifying responses to map kinase inhibition therapyBROAD INST INC·Filed 2014·Granted Apr 6, 2021·1 cites·23 claims
- 1262US2019142830A1C-RAF Mutants that Confer Resistance to RAF InhibitorsDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 1358US2022136057A9Methods of identifying responses to map kinase inhibition therapyBROAD INST INC·Filed 2021·Application pending·0 cites
- 1457US11078540B2Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapyGARRAWAY LEVI A·Filed 2017·Granted Aug 3, 2021·0 cites·12 claims
- 1557US9880169B2MEK1 mutation conferring resistance to RAF and MEK inhibitorsGARRAWAY LEVI A·Filed 2016·Granted Jan 30, 2018·0 cites·3 claims
- 1656US9084781B2MEK mutations conferring resistance to MEK inhibitorsGARRAWAY LEVI A·Filed 2009·Granted Jul 21, 2015·0 cites·13 claims
- 1756US2013143911A1MEK1 Mutation Conferring Resistance to RAF and MEK InhibitorsGARRAWAY LEVI A·Filed 2011·Application pending·0 cites
- 1855US2017204383A1C-RAF Mutants that Confer Resistance to RAF InhibitorsEMERY CAROLINE·Filed 2017·Application pending·0 cites
- 1949US2015346204A1MEK Mutations Conferring Resistance to MEK InhibitorsGARRAWAY LEVI A·Filed 2015·Application pending·0 cites
- 2049US2016299146A1Kynurenine Pathway Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor ResponseDANA FARBER CANCER INST INC·Filed 2014·Application pending·0 cites
- 2147US2020157563A1Methods of producing human cancer cell models and methods of useBROAD INST INC·Filed 2018·Application pending·0 cites
- 2246US11963966B2Compositions and methods for treating ovarian tumorsDANA FARBER CANCER INST INC·Filed 2018·Granted Apr 23, 2024·0 cites·21 claims
- 2345US2015141470A1Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapyBROAD INST INC·Filed 2013·Application pending·0 cites
- 2444US2018066322A1Biomarkers associated with cdk inhibitorsNOVARTIS AG·Filed 2017·Application pending·0 cites
- 2542US11186874B2ERK1 and ERK2 mutations that confer resistance to MAPK pathway inhibitorsDANA FARBER CANCER INST INC·Filed 2015·Granted Nov 30, 2021·0 cites·9 claims
- 2642US8637246B2BRAF mutations conferring resistance to BRAF inhibitorsGARRAWAY LEVI·Filed 2011·Granted Jan 28, 2014·0 cites·8 claims
- 2742US2013059851A1Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer TherapyGARRAWAY LEVI A·Filed 2011·Application pending·0 cites
- 2842US2018100201A1Tumor and microenvironment gene expression, compositions of matter and methods of use thereofBROAD INST INC·Filed 2017·Application pending·0 cites
- 2941US2015322528A1Biomarkers associated with cdk inhibitorsCAPONIGRO GIORDANO·Filed 2013·Application pending·0 cites
- 3039US2015354006A1Markers for acute lymphoblastic leukemiaCHAN HO MAN·Filed 2013·Application pending·0 cites
- 3137US2019367964A1Dissociation of human tumor to single cell suspension followed by biological analysisDANA FARBER CANCER INST INC·Filed 2017·Application pending·0 cites
- 3235US2018271891A1Selective treatment of prmt5 dependent cancerBROAD INST INC·Filed 2016·Application pending·0 cites
- 3332US2017081724A1Method and kits for determining sensitivity to cancer treatmentDANA FARBER CANCER INST INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Levi A. Garraway files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →